Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia
10.13699/j.cnki.1001-6821.2014.06.011
- VernacularTitle:阿立哌唑与喹硫平治疗精神分裂症的疗效与安全性
- Author:
Yong-Qiao LIU
1
;
Wei-Feng MI
;
Xiao-Zhi WANG
;
Ying SHI
;
Ling-Zhi LI
;
Wen-Bin MA
;
Chao JIN
;
Yong-Feng YANG
;
Hong-Yan ZHANG
;
Bo DU
Author Information
1. 河北省第六人民医院
- Keywords:
schizophrenia;
aripiprazole;
quetiapine;
treatment effect;
adverse drug reaction
- From:
The Chinese Journal of Clinical Pharmacology
2014;(6):505-507
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of quetiapine and aripiprazole on patients with schizophrenia.Methods The random-ized, open, multi-center trial recruited 168 patients with schizophrenia , who received a 8-week treatment of aripiprazole (n=79, 10-30 mg· d -1 ) or quetiapine ( n=89 , 400-800 mg · d -1 ).The psychotic syn-dromes were rated with the positive and negative syndrome scale ( PAN-SS)at the baseline, the end of the fourth week and the eighth week.The disease severity was evaluated by the Clinical global impression -severity scale ( CGI-S ) and the Clinical global impression -improvement scale ( CGI-I).The safety was evaluated based on the incidences of adverse events and the comparison of laboratory or electrocardiography examina-tions prior and post the treatment.Results The response rates of aripi-prazole and quetiapine were 71.4%and 72.9%.There was no statistical difference ( P>0.05 ).The incidence rates of adverse events related to aripiprazole and quetiapine were 54.05% and 41.77%.The incidence rate of extrapyramidal symptoms ( EPS ) of the two groups were 36.7%and 4.6%( P<0.001 ).Conclusion Aripiprazole and quetiapine both show similar efficacy in the treatment of schizophrenia.The incidence rates of adverse events are similar but with different profiles.
